Bile duct cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:25:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bile duct cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors. https://clinicaltrials.eu/trial/a-study-of-belzutifan-and-lenvatinib-for-patients-with-von-hippel-lindau-disease-associated-tumors-or-other-specific-solid-tumors/ Thu, 30 Apr 2026 13:08:57 +0000 https://clinicaltrials.eu/trial/a-study-of-belzutifan-and-lenvatinib-for-patients-with-von-hippel-lindau-disease-associated-tumors-or-other-specific-solid-tumors/ This study focuses on individuals with various types of cancer, including Renal Cell Carcinoma, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Esophageal Squamous Cell Carcinoma, and Pancreatic Neuroendocrine Tumor. It also includes people with Advanced Pheochromocytoma/Paraganglioma, Advanced Gastrointestinal Stromal Tumor, and certain types of Colorectal Cancer, Endometrial Cancer, or Solid Tumors that have specific genetic changes called HIF-2α related genetic alterations. Additionally, the research involves patients with von Hippel-Lindau Disease-Associated Tumors, which are tumors caused by a specific genetic condition. The purpose of the study is to evaluate the long-term effectiveness and safety of certain treatments.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

]]> A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer https://clinicaltrials.eu/trial/a-study-of-rilvegostomig-cisplatin-and-gemcitabine-compared-to-durvalumab-and-a-drug-combination-for-adults-with-advanced-biliary-tract-cancer/ Wed, 29 Apr 2026 15:09:36 +0000 https://clinicaltrials.eu/trial/a-study-of-rilvegostomig-cisplatin-and-gemcitabine-compared-to-durvalumab-and-a-drug-combination-for-adults-with-advanced-biliary-tract-cancer/ This study focuses on individuals with advanced Biliary Tract Cancer, which is a type of cancer that develops in the bile ducts, the tubes that carry bile from the liver to the gallbladder. The purpose of the study is to compare the effectiveness and safety of two different treatment approaches. One group will receive rilvegostomig combined with chemotherapy, while another group will receive durvalumab combined with chemotherapy. Chemotherapy refers to the use of powerful medicines to kill fast-growing cancer cells.

The treatment involves medications administered through an intravenous line, which means the medicine is delivered directly into a vein. Some participants may also be taking infliximab or mycophenolate mofetil as part of their ongoing background care. The study also involves the use of other medicines such as gemcitabine or cisplatin to compare how different drug combinations affect patients with certain levels of the PD-L1 protein, a substance found on some cancer cells that helps the immune system identify them.

]]> Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ Wed, 29 Apr 2026 15:03:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ This clinical trial is focused on studying the effects of a new treatment for people with advanced solid tumors that have a specific change in their genes known as a HER2 mutation. The treatment being tested is a medication called BAY 2927088, which is taken as a coated tablet. This medication is a type of drug known as a reversible tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

]]> Study on the Safety and Effectiveness of Patritumab Deruxtecan for Patients with Colorectal, Biliary Tract, and Liver Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-patritumab-deruxtecan-for-patients-with-colorectal-biliary-tract-and-liver-cancer/ Wed, 29 Apr 2026 14:58:11 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-patritumab-deruxtecan-for-patients-with-colorectal-biliary-tract-and-liver-cancer/ This clinical trial is focused on studying certain types of gastrointestinal cancers, specifically colorectal cancer, biliary tract cancer, and hepatocellular carcinoma. The treatment being tested is called patritumab deruxtecan, also known by its code name MK-1022. This medication is a special type of drug known as a monoclonal antibody, which is designed to target specific proteins in cancer cells. The purpose of the study is to evaluate the safety and effectiveness of this treatment in people with these types of cancers.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor how well the treatment is tolerated and its impact on the cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will also look at how the cancer responds to the treatment, including how long any positive effects last and whether the cancer progresses or not.

Throughout the study, researchers will collect information on any side effects experienced by participants and how the treatment affects their overall health. The study aims to provide valuable insights into the potential benefits and risks of using patritumab deruxtecan for treating these specific types of gastrointestinal cancers. The results will help determine if this treatment could be a viable option for patients in the future.

]]> Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer https://clinicaltrials.eu/trial/study-on-pembrolizumab-lenvatinib-and-belzutifan-for-patients-with-liver-colon-pancreatic-bile-duct-gallbladder-endometrial-or-esophageal-cancer/ Wed, 29 Apr 2026 14:26:22 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-lenvatinib-and-belzutifan-for-patients-with-liver-colon-pancreatic-bile-duct-gallbladder-endometrial-or-esophageal-cancer/ This clinical trial is focused on studying the effects of a combination of medications on several types of cancer, including liver cancer, colon cancer, pancreatic cancer, bile duct or gallbladder cancer, endometrial cancer, and esophageal cancer. The treatment being tested includes three medications: Pembrolizumab, also known by its code name MK-3475, which is given as an infusion into a vein; Lenvatinib, known as MK-7902, which is taken as a capsule by mouth; and Belzutifan, known as MK-6482, which is taken as a tablet by mouth. These medications are being studied together to see how well they work and how safe they are when used in combination.

The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.

]]> Study on the Effects of Volrustomig and Drug Combination for Patients with Advanced Hepatobiliary Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-volrustomig-and-drug-combination-for-patients-with-advanced-hepatobiliary-cancer/ Wed, 29 Apr 2026 14:24:15 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-volrustomig-and-drug-combination-for-patients-with-advanced-hepatobiliary-cancer/ This clinical trial is focused on studying treatments for Advanced Hepatobiliary Cancer, which includes cancers that affect the liver, gallbladder, and bile ducts. The study will explore the effectiveness and safety of new treatments called immunomodulators, which are designed to help the immune system fight cancer. These treatments will be tested both on their own and in combination with other cancer-fighting drugs. Some of the medications being studied include Gemcitabine, Cisplatin, Volrustomig (also known as MEDI5752), Bevacizumab, Lenvatinib, Rilvegostomig (also known as AZD2936), and Infliximab.

The purpose of this study is to evaluate how well these treatments work in shrinking tumors and stopping cancer from growing, as well as to assess their safety. Participants will receive these treatments through infusions, which means the medication is given directly into the bloodstream through a vein, or in the form of capsules or tablets taken by mouth. The study will last for up to 12 months, during which participants will be closely monitored by healthcare professionals to track their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on how the cancer responds to the treatments, how long the response lasts, and the overall survival of participants. They will also measure the levels of the immunomodulators in the blood and check for any immune reactions to these new treatments. This information will help determine the potential benefits and risks of these new therapies for people with advanced hepatobiliary cancer.

]]> Study on Capecitabine and Durvalumab for Patients with Removed Biliary Tract Cancer https://clinicaltrials.eu/trial/study-on-capecitabine-and-durvalumab-for-patients-with-removed-biliary-tract-cancer/ Wed, 29 Apr 2026 14:23:57 +0000 https://clinicaltrials.eu/trial/study-on-capecitabine-and-durvalumab-for-patients-with-removed-biliary-tract-cancer/ This clinical trial is focused on studying a type of cancer known as biliary tract carcinoma, which affects the bile ducts and gallbladder. The study is investigating the effectiveness of two treatments: a combination of capecitabine and durvalumab (also known by its code name MEDI4736), and capecitabine alone. Capecitabine is a medication that comes in the form of film-coated tablets, while durvalumab is given as a concentrate for solution for infusion, which means it is administered through a drip into a vein.

The purpose of the study is to evaluate how well these treatments work in preventing the return of cancer in patients who have had their biliary tract carcinoma surgically removed. The study will follow participants over a period of time to see if the cancer comes back and to assess their overall health and quality of life. Participants will be randomly assigned to receive either the combination of capecitabine and durvalumab or capecitabine alone. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The study will last for several months, with regular visits to monitor the participants’ health and response to the treatment. The main goal is to see if the combination of capecitabine and durvalumab can improve the time patients remain free from cancer compared to capecitabine alone. The study will also look at the safety of the treatments and how they affect the participants’ quality of life. This research aims to provide valuable information that could help improve treatment options for patients with biliary tract carcinoma in the future.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>